Founded in 2000, HLB Healthcare is a new drug development company that is developing innovative new drugs in the fields of eye diseases and brain tumors, and is increasing the possibility of developing the “Best-in-class” new drugs through several clinical trials in the United States.

Dry Eye Syndrome (DES) treatment
RGN-259 is an anti-inflammatory peptide that is activated in several stages of wound healing and tissue recovery as a medicinal ingredient in Thymosin beta 4. It is a multifunctional substance suitable for dry eye, a multi-personal disease such as tear deficiency or tear membrane disorder caused by excessive tear evaporation and is being developed by a U.S.-based joint venture (ReGen Tree, LLC).